CVS Health Corporation (CVS)
| Market Cap | 99.41B |
| Revenue (ttm) | 391.69B |
| Net Income (ttm) | 469.00M |
| Shares Out | 1.27B |
| EPS (ttm) | 0.37 |
| PE Ratio | 211.22 |
| Forward PE | 11.39 |
| Dividend | $2.66 (3.40%) |
| Ex-Dividend Date | Oct 23, 2025 |
| Volume | 705,858 |
| Open | 78.30 |
| Previous Close | 78.36 |
| Day's Range | 78.00 - 78.48 |
| 52-Week Range | 43.56 - 85.15 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 92.11 (+17.62%) |
| Earnings Date | Feb 11, 2026 |
About CVS
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs and Medicaid health care management services. It serves employer groups, individuals, coll... [Read more]
Financial Performance
In 2024, CVS Health's revenue was $370.66 billion, an increase of 3.93% compared to the previous year's $356.62 billion. Earnings were $4.61 billion, a decrease of -44.70%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for CVS stock is "Strong Buy." The 12-month stock price target is $92.11, which is an increase of 17.62% from the latest price.
News
Codoxo's Oversubscribed Series C Led by CVS Health Ventures to Revolutionize Payment Integrity for America's Largest Health Plans
DULUTH, Ga.--(BUSINESS WIRE)--Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, raised $35M in Series C funding, led by CVS Health Ventures. Echo Hea...
Final Trade: ETH, GM, CVS, NFLX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Gabelli Pet Parents' Fund Q3 2025 Contributors And Detractors
Chewy Inc. gained 12% during the quarter as the company delivered solid results driven by higher autoship subscription activity and expanding private-label offerings. The largest contributors to Fund ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Top Wall Street analysts are upbeat on these 3 dividend stocks for enhanced returns
TipRanks' ranking service discusses three dividend-paying stocks, including Devon Energy and CVS Health.
The consumer is frustrated right now, says CVS Health CEO David Joyner
CNBC's Jim Cramer sits down with CVS Health CEO David Joyner to discuss the company's investor day, how healthcare technology is changing, the role of artificial intelligence and more.
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak
Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the state WOONSOCKET, R.I. , Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health...
CVS Health Corporation (CVS) Analyst/Investor Day Prepared Remarks Transcript
CVS Health Corporation (CVS) Analyst/Investor Day Prepared Remarks Transcript
Cramer's Stop Trading: CVS Health
CNBC's Jim Cramer explains why he is keeping an eye on shares of CVS Health.
Buy Or Fear CVS Stock At $78?
CVS Health's (NYSE: CVS) latest results affirm several points: their sales and adjusted profits remain stable, and they are adjusting their forecasts upward. Nonetheless, the quality of their profits ...
CVS Health Hikes Its Outlook, and Says It Plans to Roll Out AI Platform
CVS wants investors to know it sees bigger profits ahead, and has new AI plans.
CVS Health: Investor Day Targets Set Attractive Baseline For 2026
CVS Health is positioned for continued outperformance, with a strong turnaround driving industry-leading results and a reiterated "Buy" rating. CVS's Q3 showed 7.8% revenue growth, 47% adjusted EPS gr...
Jim Cramer says CVS stock may be the only first-class healthcare name we have
Famed investor Jim Cramer says he “salutes” DaviCVSd Joyner after CVS Health (NYSE: CVS) raised its profit guidance for 2026 – reinforcing the new management's turnaround plan is starting to bear frui...
CVS Investor Day Highlights Major Growth Ahead - Bullish Chart Into 2026
CVS Health Corporation is a top S&P 500 performer in 2025, up 78% YTD, with strong operational and financial momentum. I reiterate a Buy rating for CVS, raising my intrinsic value target to $93, based...
CVS Health updated its 2025 guidance again, and the stock is rallying
CVS Health's stock was up about 4% at the market open on Tuesday after the company boosted its revenue and profit guidance for the year and detailed its full-year expectations for 2026.
CVS Health Outlines New Revenue Targets, AI Upgrades At Investor Day
CVS Health Inc. (NYSE: CVS) outlined its future growth plans at its investor day on Tuesday.
Cramer's Mad Dash --- CVS Health
CNBC's Jim Cramer delivers his daily Mad Dash.
CVS Health Boosts Full-Year 2025 Guidance, Sees Profit Growth in 2026
CVS Health raised its full-year outlook and guided for profit growth next year.
CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.
The healthcare company says it expects to post a narrower per-share loss in 2025.
CVS forecasts 2026 profit above estimates on strong performance
CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event
Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities Updates 2025 full-year financial guidance; ...
CVS: FY 2026 Margin Recovery, Well Covered Dividends, And Cheap Valuations
CVS remains a great Buy here, driven by the raised FY2025 adj EPS guidance and the robust outperformance against its healthcare peers despite the industrywide headwinds. Margin recovery is expected to...
CVS Health generates over $474 Billion in 2024 U.S. economic impact, supporting communities throughout the United States
New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communities WOONSOCKET, R.I. , Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) ...
Aetna expands initiatives to simplify experiences for health care professionals and patients
Bundling medical procedures and pharmaceutical medications into one prior authorization Implementing end-to-end generative AI capabilities into Aetna Health app HARTFORD, Conn. , Dec. 4, 2025 /PRNewsw...
